Status: Not yet recruiting
Therapeutics for Moderate and Severe Dengue
The purpose of this multi-site, factorial randomised, platform trial is to evaluate host-directed therapeutic agents in patients hospitalised with moderate and severe dengue virus infection. Our primary aim is to find safe and affordable therapeutics which prevent disease progression among those at high risk for severe dengue, and improve outcomes for those with established severe disease, thereby also reducing the substantial burden placed on health systems in dengue endemic regions.
Participants needed: 8,800
Trial details
Phase: Phase 3Age: 5+Biological sex: AllType: InterventionalSponsor: Oxford University Clinical Research Unit, VietnamUpdated: Apr 21, 2026Locations: 18
Eligibility criteria
Age ≥5 years [+14]
Patients on ≥ day 10 of illness or who are clinically improving in the opinion o... [+1]